Pfizer taps WuXi for new contract studies
This article was originally published in Scrip
Executive Summary
WuXi PharmaTech has struck a new three-year contract with Pfizerto conduct in vitro absorption, distribution, metabolism and excretion (ADME) studies. The firms will develop ADME assays to screen and optimise new drug compounds synthesised for Pfizer by WuXi. The Chinese contract research firm already conducts a variety of work for Pfizer, including in the synthetic and medicinal chemistry areas.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.